New Technical Integration between image analysis and PACS

Neagen and Visiopharm announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.

Visiopharm is a worldwide leader of Augmented Pathology within tissue research and diagnostics and Neagen offers a true vendor neutral enterprise imaging system based on worldwide DICOM standard.

“We are excited to see an increased demand for both workflow automation and improved interpretive accuracy from pathologists in Finland. These are the two areas where Visiopharm makes a real difference. By integrating our Augmented Pathology software with neaLink, customers can now integrate precision pathology into PACS-driven workflows, to achieve better data quality, turnaround times, and reduce manual labor”, says Michael Grunkin, CEO Visiopharm.

“Neagen sees digital pathology as indispensable in the modern pathology lab, and seamless integration into other existing diagnostic medical workflows is a pivotal requirement to successful deployment. neaLink VNA is a modern and scalable enterprise imaging solution for all medical disciplines. With this technical integration, our customers across the globe will be able to combine advanced image analysis to digital pathology with radiology in a seamlessly integrated digital workflow, to further enhance neaLink as a platform for integrated diagnostics”, says Lasse Jyrkinen, CEO Neagen.

The Oncotopix solution is compatible with and validated for all major scanner formats, and has been validated and CE-marked for the three major reagent vendors. Making Oncotopix available as a simple and seamlessly integrated plug-in to PACS and LIS systems, makes it possible to deploy and scale digital pathology in the lab, one cost-efficient and risk-free step at a time.

Source: Visiopharm/Neagen

05.09.2017